Immunotherapy master trial for advanced cancers
Part of Cancer clinical trials.
This trial tests different immunotherapy treatments for people with advanced cancer that has spread or cannot be removed by surgery. It aims to find out which treatments work best by studying your tumor and blood samples over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 years or older and weigh at least 88 pounds (40 kg).
- You have advanced cancer that has spread or cannot be removed by surgery (including leukemia or lymphoma).
- You are willing to have blood drawn and a tumor biopsy (or bone marrow sample if needed).
- You agree to use effective birth control during the study if you or your partner could become pregnant.
- You are enrolled in French social security or health insurance.
- Your kidney, liver, and blood cell counts are within certain limits (checked by blood tests).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests immunotherapy before surgery for people with localized solid tumors. It aims to improve how well the cancer is controlled and may help shrink tumors so they can be removed more easily.
This trial tests whether using immunotherapy drugs (pembrolizumab or cemiplimab) alone, without chemotherapy, can treat advanced lung cancer in people with high PD-L1 levels. It is for people who have not yet received any treatment for their advanced cancer.
This trial tests whether using a personalized approach (matching your tumor's genetic profile to a targeted drug) can help people with advanced solid cancers live longer. It is for people whose cancer is not responding to standard treatments and who have a genetic change that can be targeted by an FDA-approved drug not usually used for their cancer type.
This trial tests a new drug (GRWD5769) that may help your immune system fight cancer. It is for people with advanced solid tumors that have stopped responding to standard treatments, including certain types of cervical, liver, and other cancers.
This trial tests a new immune cell therapy for people with advanced solid tumors of the lung, liver, colon, rectum, or breast. It aims to see if the treatment is safe and can help shrink or control the cancer.
This trial tests MEDI5752, a drug designed to help the immune system attack solid tumors. It is aimed at people whose tumors have “mature tertiary lymphoid structures,” and it may be especially relevant if your cancer has not responded well enough to immune checkpoint drugs.
Hear when a new Advanced/Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.